Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments-a systematic review.

ABSTRACT:

Background

The introduction of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) has resulted in a radical change in patients' treatment responses and survival rates. The increased percentage of long survivors, improved toxicity profiles compared to chemotherapy, and the possible applications for different NSCLC scenarios, have led to immune checkpoint inhibitors (ICIs) becoming the cornerstone of NSCLC treatment. Therefore, the objective of this review is to describe the current and future perspectives of NSCLC treatment.

Methods

A systematic review according to the PRISMA criteria has been performed based on clinical trials with immunotherapy in NSCLC from the start of these treatments until June 2022.

Results

The use of ICIs is widespread across

SUBMITTER: Olivares-Hernandez A 

PROVIDER: S-EPMC10477621 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature